FDA’s Generic Drug Manufacturer Inspections Under OIG Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA notes its efforts to beef up foreign inspections in GDUFA performance report to Congress.
You may also be interested in...
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
CDER’s Woodcock says the new database will drive risk-based inspection decisions.
Culture Clash: FDA Tries to Re-Educate Indian Firms on Processes and Accurate Reporting
FDA has essentially shut down Ranbaxy’s three-year-old facility at Mohali as a source for products for the US market. But Ranbaxy is not alone among Indian firms in its quality product disputes with the agency. There is a significant uptick in activity by FDA in the region in what appears to be a period of intense culturization for the Indian firms into the ways FDA enforces cGMPs and handles on-site inspections.
FDA Quality Profiling: Agency Hopes to Channel Corporate Attention (And Money) To Quality Systems
FDA’s drug compliance leadership sees new risk assessment authority for setting inspection schedules from FDASIA as an appealing foundation for collecting and preparing profiles of drug manufacturers. Just don’t call them “report cards.”